Bipolar Disorder Clinical Trial Pipeline Analysis: 25+ Key Companies Transforming the Future of Bipolar Disorder Therapeutics | DelveInsight

DelveInsight's Bipolar Disorder (Manic Depression) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Bipolar Disorder therapies in various stages of clinical development. Major pharmaceutical companies are actively working to strengthen the Bipolar Disorder pipeline space and unlock future growth opportunities in this therapeutic domain.

Key Takeaways from the Bipolar Disorder Clinical Trial Landscape Report
• DelveInsight's Bipolar Disorder pipeline report depicts a robust landscape with 25+ active players working to develop 30+ pipeline therapies for Bipolar Disorder treatment.
• Key Bipolar Disorder companies such as Bristol-Myers Squibb, AbbVie, Autobahn Therapeutics, Reviva Pharmaceuticals, 4M Therapeutics, and others are actively evaluating novel treatment approaches.
• Promising Bipolar Disorder pipeline therapies in various stages of development include KarXT, ABBV-932, ABX-002, Icalcaprant, Brilaroxazine, and others.

Request a sample and discover the recent advances in Bipolar Disorder treatment drugs
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Bipolar Disorder?
Bipolar disorder is a long-term mental health condition in which a person experiences extreme changes in mood, energy levels, activity, and thinking. These mood changes are much stronger than normal ups and downs and can significantly affect a person's ability to carry out daily activities. Patients experience manic or hypomanic episodes characterized by elevated mood and energy, along with depressive episodes associated with sadness, hopelessness, fatigue, and reduced interest in activities.

Bipolar disorder includes Bipolar I, Bipolar II, Cyclothymic disorder, and other related mood disorders. The pathophysiology involves changes in brain structure and function, especially in regions regulating mood and emotions such as the amygdala, hippocampus, and prefrontal cortex. Diagnosis involves clinical assessment, mental health evaluation, family history review, and DSM-based diagnostic criteria. Treatment generally includes mood stabilizers, antipsychotics, antidepressants, psychotherapy, lifestyle management, and in severe cases, electroconvulsive therapy (ECT).

Emerging Bipolar Disorder Drug Profiles

ABX-002: Autobahn Therapeutics
ABX-002 is an orally administered, potent, and selective thyroid hormone beta receptor (TRβ) agonist developed to harness the CNS benefits of thyroid hormone signaling while minimizing peripheral side effects associated with synthetic thyroid hormones. The therapy targets brain bioenergetics implicated in depressive pathology and is currently in Phase II clinical development for Bipolar Disorder Depression.

KarXT: Bristol-Myers Squibb
KarXT is an oral small molecule therapy being developed by Bristol-Myers Squibb for Bipolar Disorder. The therapy functions as a muscarinic M1/M4 receptor agonist and is currently being evaluated in Phase III clinical development.

Icalcaprant: AbbVie
Icalcaprant is an investigational oral small molecule therapy being developed by AbbVie for Bipolar Disorder. The therapy acts as a KOR antagonist and is currently under Phase II clinical evaluation.

Learn more about the novel and emerging Bipolar Disorder pipeline therapies
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Bipolar Disorder Clinical Trial Landscape
• In March 2025, Autobahn Therapeutics initiated a Phase II open-label clinical trial evaluating ABX-002 in adults with bipolar depression. The study is currently recruiting participants and is expected to complete in February 2026.
• In January 2025, Autobahn Therapeutics announced initiation of a Phase II clinical trial evaluating ABX-002 as an adjunctive treatment in adults with bipolar depression.
• In October 2024, Autobahn Therapeutics announced FDA clearance of the Investigational New Drug (IND) application supporting Phase II development of ABX-002 in bipolar depression.
• In July 2024, Alto Neuroscience announced receiving USD 11.7 million from the Wellcome Trust to advance Phase IIb clinical development of ALTO-100 in patients with bipolar depression characterized by a cognitive biomarker.
• In August 2025, NRx Pharmaceuticals announced that the US FDA granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.
• In October 2024, AbbVie and Gedeon Richter announced a co-development and licensing collaboration focused on novel neuropsychiatric targets, including ABBV-932 for bipolar depression and generalized anxiety disorder.

Scope of the Bipolar Disorder Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Small molecule, Recombinant fusion proteins, Monoclonal antibody, Polymer, Peptide, Gene Therapy
• Key Bipolar Disorder Companies: Bristol-Myers Squibb, AbbVie, Autobahn Therapeutics, Reviva Pharmaceuticals, 4M Therapeutics, and others
• Key Bipolar Disorder Pipeline Therapies: KarXT, ABBV-932, ABX-002, Icalcaprant, Brilaroxazine, and others

Dive deep into rich insights for new drugs for Bipolar Disorder treatment, visit
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Bipolar Disorder Pipeline Report Introduction
2. Bipolar Disorder Pipeline Report Executive Summary
3. Bipolar Disorder Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Bipolar Disorder Pipeline Therapeutics
6. Bipolar Disorder Pipeline: Late Stage Products (Phase III)
7. Bipolar Disorder Pipeline: Mid Stage Products (Phase II)
8. Bipolar Disorder Pipeline: Early Stage Products (Phase I)
9. Bipolar Disorder Pipeline Therapeutics Assessment
10. Inactive Products in the Bipolar Disorder Pipeline
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products in the Bipolar Disorder Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Bipolar Disorder pipeline therapeutics, reach out
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

This release was published on openPR.